Skip to main content

Foundayo (Orforglipron): The First Daily GLP-1 Pill for Weight Loss

On April 1, 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 pill for chronic weight management. It's the first small-molecule GLP-1 agonist approved for weight loss, the only oral GLP-1 that can be taken any time of day without food or water restrictions, and at roughly $499 per month it sharply undercuts injectable competitors. This is the complete guide to Foundayo: how it works, what the trial data show, dosing, cost, side effects, and how it compares to Wegovy, Zepbound, and the older oral GLP-1 Rybelsus.

What Foundayo Is and Why It Matters

Foundayo is the brand name for orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly. Until April 1, 2026, every GLP-1 weight loss drug on the U.S. market was either an injection (semaglutide as Ozempic/Wegovy, tirzepatide as Zepbound/Mounjaro) or a peptide pill that demanded fasting (Rybelsus). Foundayo broke that pattern. It's a daily tablet with no food or water restrictions, no injections, and no refrigeration.

The mechanism is the same one that powered the GLP-1 revolution: activate the GLP-1 receptor in the brain, gut, and pancreas. That slows gastric emptying, increases satiety, dampens reward signaling around food, and improves glucose handling. What's new is the chemistry. Orforglipron is a non-peptide molecule small enough to survive stomach acid and absorb through the intestinal wall without an enhancer. That's the engineering breakthrough that made the pill convenient enough to compete with the injectables.

Foundayo received its approval under the FDA's Commissioner's National Priority Voucher (CNPV) program, the same expedited pathway that delivered Wegovy HD in 54 days. The FDA framed obesity as a public health priority warranting accelerated review. Foundayo is the first new molecular entity approved under CNPV, not just a new dose of an existing drug.

Clinical Evidence: ATTAIN Trial Results

Foundayo's approval rests on the ATTAIN program, four Phase 3 trials in obesity (ATTAIN-1, ATTAIN-2) and type 2 diabetes (ACHIEVE-1, ACHIEVE-2). The headline result from ATTAIN-1: at 72 weeks, adults with obesity but without diabetes lost a mean 12.4% of body weight on the 36 mg dose, versus 0.9% on placebo. That translates to roughly 27.3 lbs (12.4 kg) of weight loss for an average participant.

Around 60% of participants on the high dose hit the 10% weight loss threshold that's clinically meaningful for cardiometabolic risk reduction. About 25% lost 15% or more. These numbers slot neatly between Rybelsus 14 mg (about 4-5% weight loss in the PIONEER program) and the higher-dose injectables. For a daily pill, this is a genuine step change.

ACHIEVE-1 and ACHIEVE-2 tested orforglipron in adults with type 2 diabetes. A1C reductions reached 1.3-1.5 percentage points at the highest dose, with weight loss of around 7-9% (lower than in the obesity trials, which is typical for diabetic patients on GLP-1s). Lilly is pursuing a separate diabetes label, expected later in 2026.

How Foundayo Compares to Other GLP-1 Drugs

Efficacy ranking, mean weight loss at maximum dose, head-to-head trials where available:

  • Zepbound (tirzepatide 15 mg): ~22% weight loss
  • Wegovy HD (semaglutide 7.2 mg): ~20.7% weight loss
  • CagriSema (cagrilintide + semaglutide): ~22% in REDEFINE
  • Wegovy (semaglutide 2.4 mg): ~14.9% in STEP-1
  • Foundayo (orforglipron 36 mg): ~12.4% in ATTAIN-1
  • Saxenda (liraglutide 3.0 mg): ~6-8% in SCALE
  • Rybelsus (semaglutide 14 mg, off-label for weight loss): ~4-5%

On efficacy alone, Foundayo trails the high-dose injectables. On convenience, route of administration, and price, it leads. The right comparator depends on what you're optimizing for: see Foundayo vs Wegovy and Foundayo vs Zepbound for head-to-head breakdowns.

Foundayo Dosing Schedule

Foundayo follows a slow titration to manage GI side effects, similar to other GLP-1s. The standard escalation:

  • Weeks 1-4: 3 mg once daily (starting dose)
  • Weeks 5-8: 6 mg once daily
  • Weeks 9-12: 12 mg once daily
  • Weeks 13-16: 24 mg once daily
  • Week 17 onward: 36 mg once daily (maintenance)

Patients can stay at lower maintenance doses (12 mg or 24 mg) if those provide adequate weight loss with better tolerability. Foundayo is taken at any time of day with or without food, with no waiting period before eating or drinking. That's the operational difference vs Rybelsus and the reason most prescribers will steer oral-preferring patients to Foundayo. For comparison, see Wegovy dosing schedule and tirzepatide dosage chart.

Foundayo Cost and Insurance Coverage

Lilly priced Foundayo at approximately $499 per month list price, lower than the typical $1,300-$1,500 list price for Wegovy or Zepbound. Eli Lilly is selling Foundayo direct-to-consumer through LillyDirect for cash-pay patients, alongside traditional pharmacy distribution.

Manufacturer savings cards bring out-of-pocket costs to $25/month for eligible commercially insured patients, similar to Lilly's existing Zepbound savings program. Medicare and Medicaid typically don't cover GLP-1s for weight loss alone, though Foundayo's lower price may make state Medicaid programs more willing to add it to formularies. The same applies to commercial plans that have refused Wegovy and Zepbound on cost grounds.

For context on what GLP-1 medications cost without insurance, see semaglutide cost without insurance, Zepbound cost without insurance, and tirzepatide without insurance.

Side Effects and Tolerability

Foundayo's side effect profile tracks closely with the rest of the GLP-1 class. The most commonly reported adverse events from ATTAIN-1, in order of frequency:

  • Nausea (about 30%, most often during titration)
  • Diarrhea (about 20%)
  • Constipation (about 18%)
  • Vomiting (about 15%)
  • Indigestion / dyspepsia (about 12%)
  • Abdominal pain (about 10%)
  • Decreased appetite (about 10%)
  • Headache, fatigue, belching, heartburn, gas (each 5-10%)
  • Hair loss (about 5%, similar to Wegovy hair loss)

Most GI symptoms peak during dose escalation and fade by week 4-8 at each new dose level. Slowing the titration is the standard fix when nausea is intolerable. Serious adverse events from the GLP-1 class apply: pancreatitis, gallbladder disease, severe GI events, and the boxed warning for medullary thyroid carcinoma based on rodent studies. Foundayo carries the same warnings.

One caveat unique to oral GLP-1s: because absorption depends on the GI environment, patients with severe gastroparesis or recent bariatric surgery may have unpredictable drug exposure. Injectable GLP-1s avoid that variability.

Who Should Consider Foundayo

Good candidates for Foundayo:

  • Adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities who refuse injections
  • Patients with documented needle phobia (a real clinical condition, not just dislike)
  • Frequent travelers who can't reliably refrigerate injectable GLP-1s
  • Patients on tight cash-pay budgets who can't afford Wegovy or Zepbound list prices
  • Patients on Rybelsus who struggle with the fasting requirement
  • Patients targeting moderate weight loss (10-15%) rather than maximal weight loss

Less ideal candidates:

  • Severe obesity (BMI 40+) where higher-efficacy injectables produce better outcomes
  • Patients with type 2 diabetes who need both glycemic control and substantial weight loss (Zepbound usually wins)
  • Patients with severe gastroparesis or significant gut anatomy alterations
  • Personal or family history of medullary thyroid carcinoma or MEN 2

How to Get Foundayo

As of April 2026, Foundayo is available through:

  • LillyDirect: Eli Lilly's direct-to-consumer telehealth platform handles consultation, prescription, and home delivery for cash-pay patients
  • Major retail pharmacies: Walgreens, CVS, Costco, and most independent pharmacies stock Foundayo
  • Telehealth weight loss platforms: Most have added Foundayo to formulary alongside compounded GLP-1s; see Ro, Calibrate, and Sequence
  • Primary care and obesity medicine practices: In-person prescribing, often with insurance run for coverage

For broader context on how to access GLP-1 medications and what to expect from the consultation process, see telehealth GLP-1 visit, what labs before GLP-1, and the complete list of GLP-1 medications.

Foundayo vs Compounded GLP-1s

The economics of Foundayo's $499 list price create direct pressure on the compounded GLP-1 market. Compounded semaglutide and tirzepatide typically run $250-$400 per month, partly because patients couldn't afford brand pricing. Foundayo at $499 with savings card programs starts to close that gap. Patients who chose compounding for cost reasons rather than principle now have an FDA-approved oral option in striking range.

That said, Foundayo cannot itself be compounded. Orforglipron is patent-protected, in active commercial supply, and not on the FDA shortage list. Compounding pharmacies have no legal pathway to make it. Any vendor advertising compounded orforglipron is operating outside FDA rules. For comparisons, see cheapest compounded semaglutide, cheapest compounded tirzepatide, and semaglutide compounding pharmacy.

What Foundayo Means for the GLP-1 Market

Foundayo's arrival changes three things in the obesity drug market. First, it eliminates the injection barrier for a meaningful share of patients. Roughly 15-25% of GLP-1 candidates decline therapy because of needle aversion. An effective oral option captures that population.

Second, the $499 list price puts downward pressure on Wegovy and Zepbound. Novo Nordisk and Eli Lilly have already started discounting through their direct-to-consumer channels (NovoCare and LillyDirect). Foundayo's pricing pressure accelerates that trend.

Third, Foundayo demonstrates that small-molecule GLP-1 agonists are commercially viable. Pfizer, Roche, AstraZeneca, and several biotech firms have oral GLP-1 candidates in Phase 2 or 3. Expect 2-4 additional oral GLP-1s on the U.S. market within 18-24 months. Many will compete on price and side effect profile rather than efficacy. The injectables retain a clear weight loss advantage at the high dose levels (Wegovy HD, Zepbound 15 mg, retatrutide pending), but the oral category is now legitimate and growing.

For more on the broader GLP-1 landscape and the next-generation drugs in development, see retatrutide, CagriSema, survodutide, and which GLP-1 is best for weight loss.

Bottom Line

Foundayo is the first daily oral GLP-1 pill that delivers meaningful weight loss without injections or fasting requirements. Mean 12.4% weight loss is real, the price is competitive, and the operational simplicity (any time of day, with or without food) is a genuine advantage. It won't displace Zepbound or Wegovy HD for patients chasing maximal weight loss, but for the large population of GLP-1 candidates who've declined treatment because of injection aversion or fasting requirements, Foundayo is a practical first-line option starting now.

Frequently Asked Questions About Foundayo

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management. The FDA approved it on April 1, 2026 under the Commissioner's National Priority Voucher (CNPV) program. Unlike Rybelsus (oral semaglutide), Foundayo can be taken any time of day with or without food or water.

Yes, Foundayo activates the GLP-1 receptor, the same target as Ozempic, Wegovy, and Rybelsus. The difference is that Foundayo is a small-molecule drug, not a peptide. Peptide GLP-1 agonists like semaglutide degrade in the stomach unless injected or wrapped in absorption enhancers (as in Rybelsus). Foundayo's small-molecule design survives digestion intact, which is why it can be taken without food or water restrictions.

In the ATTAIN-1 obesity trial, adults on the highest dose of Foundayo (36 mg) lost a mean 12.4% of body weight (about 27.3 lbs / 12.4 kg) over 72 weeks, compared with 0.9% on placebo. Roughly 60% of patients lost at least 10% of their starting weight. Results sit between Wegovy (about 15%) and Zepbound (about 22%), but with the convenience of a daily pill.

Both are oral GLP-1 medications, but they're very different. Rybelsus is oral semaglutide and must be taken on an empty stomach with no more than 4 oz of plain water, then no food or other medication for at least 30 minutes. Foundayo can be taken any time of day with or without food or water. Rybelsus is FDA-approved for type 2 diabetes only, while Foundayo is FDA-approved for chronic weight management.

Eli Lilly's announced list price for Foundayo is approximately $499 per month at the highest dose, undercutting most injectable GLP-1s. With manufacturer savings cards, eligible commercially insured patients may pay as little as $25 per month. Without insurance, expect $400-$500 monthly through Lilly's direct-to-consumer pharmacy channels and major retailers like Walgreens and CVS.

The most common side effects mirror other GLP-1 drugs: nausea (around 30%), diarrhea, constipation, vomiting, indigestion, abdominal pain, headache, fatigue, belching, heartburn, gas, and hair loss. Most GI symptoms appear during dose escalation and improve over 4-8 weeks. Foundayo carries the same boxed warning as other GLP-1s for thyroid C-cell tumors based on rodent studies.

Foundayo lands between Rybelsus and the injectables on efficacy. At the 36 mg dose, mean weight loss is roughly 12.4%, compared with 14.9% for Wegovy 2.4 mg, 20.7% for Wegovy HD 7.2 mg, and 20-22% for Zepbound at 15 mg. For someone wanting maximal weight loss, the injectables still win. For someone who refuses needles or has needle phobia, Foundayo is the most effective oral option available.

Foundayo is FDA-approved for adults with a BMI of 30 or higher (obesity), or BMI 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. It's contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Foundayo is available as of April 2026 through Eli Lilly's LillyDirect telehealth platform, major retail pharmacies (Walgreens, CVS, Costco), and most telehealth weight loss services. You'll need a prescription from a licensed clinician. Some practices have already updated their formularies to include Foundayo as a first-line oral option for patients who decline injections.

No. Foundayo (orforglipron) is patent-protected, in active commercial supply, and not on the FDA shortage list. That means it cannot legally be compounded by 503A or 503B pharmacies. Anyone advertising compounded orforglipron is operating outside FDA rules and the product likely lacks pharmacopoeial identity testing.